Evaluation of Stem Cell-Derived Cellular Therapy Products

Area of Science:

• Cellular Therapy
• Preclinical Study Design
• Regulatory Science

Background:

• Increasing development of novel cellular therapies necessitates robust preclinical study guidelines.
• Current guidelines for preclinical cellular therapy studies are limited.
• Each cellular therapy product and its intended use require a unique, case-by-case regulatory approach.

Purpose of the Study:

• To highlight critical considerations for designing effective preclinical studies for cellular therapies.
• To emphasize the importance of pathologist involvement in early study design.
• To advocate for comprehensive tissue retention for potential future analyses.

Main Methods:

• Review of current practices in cellular therapy development.
• Analysis of regulatory expectations for preclinical studies.
• Consultation with veterinary pathology expertise.

Main Results:

• Preclinical study design must be tailored to each specific cellular therapy product.
• Early and continuous pathologist input is crucial for animal selection, marker identification, and tissue examination.
• Retaining all study tissues is vital for investigating unexpected clinical outcomes.

Conclusions:

• Standardized guidelines for preclinical cellular therapy studies are lacking.
• A case-by-case approach, guided by pathology expertise, is essential for robust study design.
• Comprehensive tissue retention enhances the scientific integrity and long-term value of preclinical cellular therapy studies.